NASDAQ:STOKStoke Therapeutics Stock Price, Forecast & News

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STOK shares have increased by 34.9% and is now trading at $26.61. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stoke Therapeutics.

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Stoke Therapeutics.

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings data on Friday, May, 15th. The company reported ($0.34) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.36) by $0.02. View Stoke Therapeutics' earnings history.

7 Wall Street analysts have issued 12-month price objectives for Stoke Therapeutics' shares. Their forecasts range from $30.00 to $46.00. On average, they expect Stoke Therapeutics' share price to reach $36.50 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View analysts' price targets for Stoke Therapeutics.

Media coverage about STOK stock has trended very negative on Wednesday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stoke Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutStoke Therapeutics.

Stoke Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,910,000 shares, an increase of 6.2% from the April 15th total of 2,740,000 shares. Based on an average daily trading volume, of 233,100 shares, the short-interest ratio is presently 12.5 days. Approximately 18.6% of the shares of the stock are short sold. View Stoke Therapeutics' Current Options Chain.

Some companies that are related to Stoke Therapeutics include Deciphera Pharmaceuticals (DCPH), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), Allakos (ALLK), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Arena Pharmaceuticals (ARNA), Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Insmed (INSM) and Intercept Pharmaceuticals (ICPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Akero Therapeutics (AKRO), LogicBio Therapeutics (LOGC), Precision BioSciences (DTIL), Gilead Sciences (GILD), Atreca (BCEL), Homology Medicines (FIXX) and Harpoon Therapeutics (HARP).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (6.57%), Cormorant Asset Management LP (5.19%), BlackRock Inc. (4.16%), Federated Hermes Inc. (2.52%), Janus Henderson Group PLC (1.61%) and State Street Corp (0.89%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Gene Liau, Huw M Nash and Rtw Investments, Lp. View institutional ownership trends for Stoke Therapeutics.

STOK stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Sphera Funds Management LTD., Cormorant Asset Management LP, Wellington Management Group LLP, Morgan Stanley, Casdin Capital LLC, Ensign Peak Advisors Inc, and UBS Group AG. Company insiders that have sold Stoke Therapeutics company stock in the last year include Gene Liau, Huw M Nash, and Rtw Investments, Lp. View insider buying and selling activity for Stoke Therapeutics.

STOK stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Lord Abbett & CO. LLC, State Street Corp, Geode Capital Management LLC, Nuveen Asset Management LLC, Federated Hermes Inc., and Bank of New York Mellon Corp. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp. View insider buying and selling activity for Stoke Therapeutics.

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STOK stock can currently be purchased for approximately $26.61.

Stoke Therapeutics has a market capitalization of $877.33 million. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe.

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]